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 ABSTRACT
Subclinical rejection following renal transplant is associated with worse outcomes, which can be pre-
vented if recognized early. Protocol allograft biopsies have emerged as an option to identify and allow 
treatment of subclinical rejection, but optimal timing for their performance is not established.
We retrospectively evaluated a cohort of 52 low immunological risk patients, who were submitted, from 
2007 to 2010, to de novo renal transplant. We separated them into two groups depending on performing 
an early graft protocol biopsy before hospital discharge: Group A – 32 patients (61.5%) performed a pro-
tocol biopsy, and group B – 20 patients (38.5%) did not, the biopsy being considered not essential for 
various reasons. We analysed patients’ demographics, biopsy complications, graft function, rejection epi-
sodes, and patient and graft survival for a median follow-up time of 63.3 months (50.3-83.7).
Group A and group B differed in gender (more female patients were biopsied), dialysis vintage (higher 
in group A), human leucocyte antigen mismatch (higher in group A), and induction protocol (more patients 
submitted to thymoglobulin than to basiliximab in group A). Protocol biopsy detected histological changes 
in four patients (12.5%) in group A (2 cellular and 2 borderline rejections), and all were treated accordingly. 
Moderate peri-graft hematoma was reported in two cases (3.9%). Despite the increased risk in group A, 
renal function at discharge was better than in group B (p < 0.05 for serum creatinine and eGFR). During 
follow-up, rejection episodes were similar in the two groups. By the end of follow-up (median 63.3 mon-
ths), proteinuria and renal function were similar between the two groups. Using a multivariate regression 
model, and despite the initial differences, at the end of follow-up, patients submitted to early protocol 
biopsies had similar excellent prognosis as the very low-risk patients who were not biopsied. (p = 0.5).
Following our results, we propose that timing of early protocol biopsy should be individualized according 
to the patient’s clinical and immunological risk.
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 INTRODUCTION
Even in the current state of the art, acute kidney 
graft rejection remains a serious risk after transplan-
tation. Subclinical rejection (SCR) – biopsy-proven 
graft injury despite normal and stable renal function 
– has been recognized for more than 30 years. This 
condition leads to a higher risk of interstitial fibrosis 
and tubular atrophy (IF/TA)1, and chronic antibody-
mediated rejection2. Early recognition and treatment 
of these changes correlates with better graft out-
comes3,4. Such early changes are inefficiently 
detected by current serum and urinary biomarkers, 
and are only diagnosed with renal biopsy. Protocol 
kidney transplant biopsies (PBx) are regarded as a 
mean to fill this gap and safeguard graft function. 
They have proven to be effective in detecting sub-
clinical rejection and are routinely performed in 
transplantation units worldwide.
Current focus is now on individualizing PBx 
performance in order to extract maximum benefit 
from an invasive procedure. For example, patients 
under an immunosuppression-minimization strategy 
are at higher risk of rejection and benefit from early 
(< 3 months) biopsy, while higher risk grafts should 
be biopsied during the first few weeks. The optimal 
biopsy timing for patients with a lower immunologi-
cal risk is still under debate.
In our centre, cadaveric renal transplant patients 
are submitted to PBx since 2007, and nowadays most 
of our de novo cadaveric renal transplant (RT) 
patients undergo a PBx before hospital discharge. In 
the present study, our primary aim was to compare, 
in a low immunological risk population, medium-term 
renal outcome, based on renal function and clinical 
evolution of those who were submitted to PBx with 
those who did not, in an attempt to document ben-
efits of very early PBx. Secondary aims were to 
evaluate the rate of biopsy complications, and patient 
outcomes as a composite end point of death and 
graft loss.
 RESUMO
A rejeição subclínica após transplante renal está associada a pior desfecho, que é prevenível se reco-
nhecida precocemente. As biópsias protocoladas surgiram como uma opção para identificar e tratar a rejeição 
subclínica, embora o timing ideal para realização da mesma não esteja estabelecido.
Avaliámos retrospectivamente uma coorte de 52 doentes transplantados renais de novo de 2007 a 2010, 
com baixo risco clínico e imunológico. Obtivemos 2 grupos baseados na realização ou não de biópsia precoce 
protocolada do enxerto: Grupo A – 32 doentes (61,5%) foram submetidos a biópsia protocolada previamente 
à alta hospitalar, e Grupo B – 20 doentes (38,5%) em que a biópsia protocolada foi dispensada, por motivos 
diversos. Analisámos dados demográficos, complicações da biópsia, função do enxerto, episódios de rejeição 
e sobrevida do enxerto e dos doentes durante um período de seguimento de 63,3 meses (50,3-83,7).
Os doentes do grupo A e do grupo B eram diferentes no que diz respeito ao género (mais mulheres no 
grupo A), tempo prévio em diálise (maior no grupo A), human leucocyte antigen mismatch (maior no grupo 
A) e protocolo de indução (mais doentes submetidos a timoglobulina do que basiliximab no grupo A). As 
biópsias protocoladas documentaram alterações histológicas em quatro doentes (12,5%) do grupo A (2 
rejeições celulares e 2 borderline), todas tratadas. Registaram-se dois hematomas moderados peri renais 
(3,9% das biópsias). Apesar do risco mais elevado do grupo A, função renal à altura da alta era melhor 
do que no grupo B (p < 0,05 para creatinina sérica e eGFR). Durante o seguimento dos doentes, o número 
de rejeições foi idêntico nos dois grupos. No final do seguimento (mediana de 63,3 meses), a proteinúria 
e a função renal eram semelhantes nos dois grupos. No modelo de regressão multivariada, e apesar das 
diferenças clínicas iniciais, os doentes submetidos a biópsias protocoladas apresentaram resultados exce-
lentes, semelhantes aos doentes de risco mínimo, não biopsados (p = 0,5).
O momento da realização da biópsia protocolada precoce deve ser ajustado de acordo com o risco clínico 
e imunológico do doente.
Palavras-Chave: Biópsia enxerto renal; biópsia protocolada; rejeição subclínica; transplante renal.
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 SUBJECTS AND METHODS
This is a retrospective descriptive analysis, using 
data from patient files, of an open cohort of 52 low 
risk patients submitted to cadaveric de novo renal 
transplants between January 2007 and December 2010.
Inclusion criteria were: patients submitted to a 
first renal transplant, with induction protocol based 
on basiliximab or thymoglobulin (when mismatches 
were higher than 4), and maintenance immunosup-
pression based on Tacrolimus (TAC), Mycophenolate 
Mofetil (MMF) and Prednisolone (PDN).
Exclusion criteria included patients with panel 
reactive antibody (PRA) superior to 20%, living-
donor transplant, previous renal transplant, multi-
organ transplant, patients that died or lost graft 
function before hospital discharge, and those who 
had a clinical reason for renal biopsy (e.g., delayed 
graft function).
Low immunological risk definitions vary widely 
between transplantation units. We considered patients 
with a PRA lower than 20%, submitted to single-
organ, first renal transplant. HLA mismatches were 
not considered, hence the inclusion of patients 
whose induction protocol included basiliximab or 
thymoglobulin.
Patients were divided in two groups: those who 
were discharged after PBx were included in group 
A, and those who were discharged without PBx were 
included in group B. Reasons for not proceeding 
with PBX were mainly logistical (e.g., high influx of 
patients), and resulted from a positive selection not 
to perform routine biopsy.
We analysed transplant receptors and organ 
donors demographic data (age, gender, race), stud-
ied period medication (including immunosuppres-
sion, antihypertensive medication, statin, allopuri-
nol), time of protocol biopsies, protocol biopsies 
results (IFTA, presence and type of rejection), 
protocol biopsies complications, medical complica-
tions after transplantation (rejection, new onset 
diabetes after transplant –NODAT, hypertension, 
peripheral artery disease), proteinuria at the end 
of follow-up, graft function and graft and patient 
survival. Donor-specific antigens (DSA) were report-
ed, when available.
On average, biopsies were performed on the 12th 
day post-transplant. Biopsy was performed under 
ultrasound guidance, with a 14-gauge needle, obtaining 
one core. Biopsies were evaluated in our Renal Mor-
phology Unit, according to the Banff 2007 classification. 
Histologic optic examination was performed with hae-
matoxylin and eosin, periodic acid–Schiff, silver and 
Masson’s trichrome stains; immunofluorescence study 
include studies with antibodies against IgG, IgA, IgM, 
C3 and fibrinogen; immunohistochemistry transplant 
panel (C4d, SV40) was performed in all biopsies.
Graft function was monitored by serum creatinine 
and eGFR using the CKD-EPI equation. Tacrolimus 
trough levels goal was 8-12 ng/ml until month 3 
after transplant, and 6-8 ng/ml thereafter. The Hos-
pital’s Central Laboratory performed all laboratory 
measurements.
Data are presented as frequencies for categorical 
variables; continuous variables are presented as 
mean ± SD values, when normally distributed, or as 
median (interquartile range) otherwise.
Comparisons between the 2 studied groups were 
performed using qui-squared test (for frequencies) 
and t-test or Wilcoxon for continuous variables, 
depending on normality. P-values were reported.
After this first analysis, we performed a univariate 
and a multivariate analysis using all subjects, and 
defining graft function as our outcome and PBx as 
our main predictor. In order to do that, and because 
we were not allowed to perform a linear regression 
(performing a PBx is not linearly correlated with graft 
function), we created a new binary variable of graft 
function, dividing patients according to their final 
eGFR (> or < to 60 ml/min/1.73m2 – chronic kidney 
disease stage 3A). We reported p-values, odds ratios 
(OR) and the 95% confidence interval (95% CI).
All tests were performed using STATA software 
version 13, and a p-value < 0.05 was considered 
statistically significant.
 RESULTS
From 2007 to 2010, 214 patients were submitted 
to renal transplant in our transplant unit. Fifty-two 
David Navarro, Ana Carina Ferreira, Fernando Caeiro, Patrícia Cotovio, Inês Aires, Cecília Silva, 
Francisco Remédio, Aníbal Ferreira, Helena Viana, Fernanda Carvalho, Fernando Nolasco
Nefro - 29-4 - MIOLO.indd   318 06/01/2016   11:25:59
Port J Nephrol Hypert 2015; 29(4): 316-322    319
Early renal protocol biopsies: for some but not for all renal transplant patients?
patients met the inclusion criteria: 32 patients 
(61.5%) underwent PBx before hospital discharge 
– group A – and 20 (38.5%) did not – group B.
The 52 patients were evaluated during a median 
follow-up of 63.3 months (48.3-98.6). Minimum 
follow-up was 4 years. Mean age was 52.7 ± 12 
years, and there were 32 males (61.5%), and 10 
diabetics (19.2%). The population had a median 
haemodialysis vintage of 65.4 months (38.3-120). 
Median panel reactive antibody (PRA) was 0%. 
Donor gender was mostly female (n = 27, 51.9%), 
average donor age was 47.3 ± 17 years, average 
human leucocyte antigen (HLA) mismatch of 3.8 ± 
1.5 and mean cold ischaemia time of 16.8 ± 4.4 
hours. Induction protocol was based in Basiliximab 
in 35 patients (67.3%), and thymoglobulin in 17 
patients (32.7%).
As shown in Table I, groups A and B did not differ 
in age, PRA, presence of DM/NODAT or other comor-
bidities, cold ischaemia time or donor characteristics. 
The 2 groups differed in gender [80% of female 
patients underwent PBx, versus 50% of male 
patients (p = 0.03)]; dialysis vintage [75.6 (59-122.2) 
vs. 38.3 (25.5-103.3) months, p = 0.03)], and HLA 
mismatch number (Group A 4.16 vs. Group B 3.25, 
p = 0.03). The majority of patients in the anti-lym-
phocyte protocol (14/17) did a PBx (p = 0.04). At 
discharge, serum creatinine was lower in group A 
(1.3 ± 0.4 vs. 1.6 ± 0.4 mg/dl, p = 0.009), with a 
trend to higher eGFR (62.1 ± 23.3 vs. 49.8 ± 17.4, p 
= 0.05). Both groups had similar hospital stay 
duration. Even so, at the end of follow-up there were 
no differences in renal function. Nevertheless, 
patients in group B were followed more time than 
patients in group A. Using proteinuria as a surrogate 
marker of graft lesion, there was also no differences 
between the two groups.
Regarding histology, 32 patients underwent PBx 
(group A) and sample quality was good, with on 
average 12 glomeruli (3-26). Histological changes 
were detected in 4/32 cases (12.5%) – 2 cellular 
rejections and 2 borderline rejections – all of which 
were treated with steroids, except in 1 case with 
thymoglobulin. All biopsies were C4d and SV40 
negative. Maintenance immunosuppression remained 
unchanged in these 4 cases. PBx was complicated 
by moderate hematoma in 2 cases (3.9%); no other 
adverse events were reported.
During follow-up, 17 patients developed NODAT 
(32.7%), 36 were reported as hypertensive (69.2%), 
seven had peripheral arterial disease (13.7%), 35 
dyslipidaemia (67.3%) and nine hyperuricemia 
(9.6%); 17 patients (33.3%) were under ACEi/ARBs, 
29 (57%) with statin and eight (15%) with 
allopurinol.
During this time, the number of rejection episodes 
was similar in the two groups: two humoral rejec-
tions in group A (1 acute and 1 chronic humoral 
rejections) and 1 acute cellular rejection in group B. 
The two patients in group A who had humoral rejec-
tion during follow-up did not have SCR diagnosed 
Table I
Clinical characteristics of the study population
Group A (PBx) Group B (no biopsy) p
N 32 20
Age (years) 51.3 ± 12.8 54.9 ± 10.3 NS
Male / female 16 / 16 16 / 4 0.03
Diabetic (n / %) 5 / 15.6% 5 / 25% NS
Dialysis vintage (months) 75.6 (59 -122.2) 38.3 (25.5 – 103.3) 0.03
PRA (median) 0 0 NS
Donor gender male / female 16 / 16 9 / 11 NS
Donor age 47.5 ± 16 47 ± 18.8 NS
HLA mismatches 4.16 ± 1.4 3.25 ± 1.3 0.03
Thymoglobulin use (n / %) 14 / 43.7% 3 / 15% 0.04
Cold ischaemia (hours) 16.3 ± 3.7 17.5 ± 5.3 NS
Serum creatinine at discharge (mg/dl) 1.3 ± 0.4 1.6 ± 0.4 0.009
CKD-EPI at discharge (ml/min/1.73m2) 62.1 ± 23.3 49.8 ± 17.4 0.05 
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on PBx. During follow-up, 38 patients (73%) had 
one or more anti-HLA screening. A total of eight 
patients (21%) had a positive donor-specific antigen 
(with mean fluorescence intensity of 1850 ± 828.1), 
and an additional 20 patients (38.5%) had a non-
donor-specific antigen (mean fluorescence intensity 
of 2475.2 ± 2186.7). Having a positive anti-HLA 
positive screening test did not correlate with worse 
renal outcome.
By the end of follow-up, five patients (9.8%) died 
– two in group A and three in group B – and two 
(3.9% – one in each group) lost graft function. The 
composite end point of death or loss of graft func-
tion was not different between the groups (p = 0.3). 
Average final serum creatinine was 1.41 ± 0.4 mg/dl, 
and CKD-EPI eGFR was 56.5 ± 21.8 ml/min/1.73m2. 
Follow-up details for both groups are summarized 
in Table II.
After this first analysis, we performed a univariate 
analysis in order to establish independent predictors 
of worse renal function in long-term (eGFR < 60 ml/
min/1.73m2). We found the following independent 
predictors: higher receptor’s age (p = 0.05), higher 
donor’s age (p = 0.01), dialysis vintage (p = 0.04), 
and eGFR at discharge (p = 0.04). Performing PBx 
(p = 0.5), was not a predictor of renal function at 
the end of the study.
In the multiple regression model (Table III), using 
PBx, receptor’s age, donor’s age, dialysis vintage, 
eGFR at discharge, gender, anti-HLA test result, HLA 
mismatch and induction protocol type, we found 
only dialysis vintage (OR 1.06, 95%CI 1.01-1.11, p = 
0.019) to be a significant predictor for worse renal 
function (eGFR < 60 ml/min/1.73m2) -meaning that 
for each year on waiting list the odds of worst renal 
function is 12.7 times higher. There was a trend for 
significance in donor’s age (OR 1.11, 95% CI 1-1.25, 
p = 0.09). Nor PBx, (p = 0.38) not even eGFR at 
discharge (p = 0.08) were independent predictors 
of renal outcome.
 DISCUSSION
We currently rely on serum creatinine for graft 
function vigilance, but it is an insensitive biomarker 
of renal injury, in particular at a GFR of 50-90 ml/
min/1.73m2 5. Subclinical rejection is associated with 
worse outcomes and Rush D and co-workers3 have 
Table II
Follow-up of the study population
Group A (PBx) Group B (no biopsy) p
FUP time (months) 58 (48.3 – 65.7) 86.3 (62.8 – 93.6) 0.002
Diabetic / NODAT (n / %) 12 / 37.5% 5 / 25% NS
HTA 4 / 12.5% 2 / 10.5% NS
Peripheral artery disease (n / %) 4 / 12.5% 3 / 15.7% NS
Dyslipidemia (n / %) 21 / 65.6% 14 / 70% NS
Hyperuricemia (n / %) 7 / 21.9% 2 / 10.5% NS
Proteinuria (g/24h) 0.1 (0-0.37) 0.05 (0 – 0.13) 0.09
Serum creatinine at end of FUP 1.5 ± 0.5 1.3 ± 0.3 NS
CKD-EPI at end FUP (ml/min/1.73m2) 55.3 ± 25.8 58.4 ± 13.2 NS
Deaths (n / %) 2 / 6.4% 3 / 15% NS
Graft loss (n / %) 1 / 3.1% 1 / 5% NS 
Table III
Multivaried regression analysis
Graft function (EPI < 60 ml/min)
Odds ratio p-value
PBx 0.20 0.38
Female gender 2.1 0.56
HLA mismatches 0.64 0.27
Positive anti-HLA result 1.18 0.92
Induction protocol 9.2 0.2
Donor’s age 1.11 0.09
Age 0.92 0.37
Dialysis vintage 1.06 0.019
CKD-EPI at discharge 0.93 0.08 
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proven that they can be prevented with adequate 
treatment, in particular if detected at an early stage. 
Hence, protocol biopsies, at pre-specified times, have 
emerged as an appropriate option to detect SCR. We 
have undertaken a small retrospective study of low 
immunological risk patients, at a single centre, to 
compare the outcomes of those submitted to early 
protocol allograft biopsy versus those who were not.
The PBx have a number of disadvantages that 
should be considered when engaging in such a 
programme. Despite being a frequent procedure in 
transplant units worldwide, allograft biopsies are an 
invasive procedure with well-documented adverse 
events. In the era of ultrasound-guided biopsies, 
major complications are infrequent, happening in 
0.4-1.0% of biopsies6,7. Reported complications in 
our study were somewhat higher (3.9%, two 
patients); there was no mortality and no graft loss 
relating to PBx.
Early course biopsies (< 3 month) are useful in 
detecting SCR, while biopsies performed from 3-12 
months additionally identify BK virus nephropathy 
and CNI toxicity. Findings in PBx after 12 months 
tend to have a low yield of reversible disease and 
are not routinely performed5. It is clear that SCR is 
more frequent in the first few months after RT, but 
estimates of its prevalence are extremely variable in 
the literature – 1 to 60%8. This is probably due to 
variations in timing of biopsy, HLA mismatch and 
level or type of baseline immunosuppression. The 
latter is particularly relevant, since modern immuno-
suppression has led to a decreasing prevalence of 
early subclinical rejection, with protocols combining 
MMF and TAC having a notably lower SCR inci-
dence9,10. This has led to the trial by Rush et al.11 
where a lack of benefit for PBx at < 6 months interval 
was demonstrated in patients under a protocol of 
MMF, TAC and PDN, probably due to the low inci-
dence of SCR (4.6% in that study).
In our study we compared a group where a deci-
sion was taken not to perform the protocol biopsy, 
due mainly to logistical reasons, and based on the 
maximum likelihood of excellent clinical prospect 
(group B), with a normal low risk patients (group 
A). This was evident on the excellent characteristics 
of group B when compared to group A, where some-
what higher risk patients were included, as evi-
denced in Table I.
As expected, we found an important SCR inci-
dence (12.5%) in the PBx group, and all were treated 
accordingly. Despite the increased risk for group A 
patients (higher dialysis vintage, more HLA mis-
matches, more use of thymoglobulin), we did not 
observe worse outcomes when compared to group 
B (no biopsy). The number of rejection episodes 
during FUP was not statistically different in the two 
groups: 2 humoral rejections in group A and 1 cel-
lular rejection in group B, but again higher risk 
humoral rejections were only observed in group A. 
Despite the association of borderline and SCR rejec-
tion with higher incidence of subsequent acute 
rejection12, no evidence of rejection was present in 
the early PBx of these two group A patients who 
developed humoral rejection.
We also found no differences regarding eGFR or 
proteinuria at end of follow-up. In order to account 
for these factors, we performed a multivariate analy-
sis, which did not show any differences between 
these 2 different risk groups.
Ideal timing for PBx is not established, partially 
because there are other factors in play besides SCR 
– BK nephropathy and CNI toxicity are the ‘other 
side of the coin’ of our current more potent immu-
nosuppression. Our patients were submitted to PBx, 
on average, 12 days after transplant, so it is not 
surprising that we did not observe any episode of 
BK nephropathy or CNI toxicity.
This study has a number of limitations: it is a 
retrospective study, with a low number of patients 
that were submitted to PBx obtaining only one core. 
The higher HLA mismatch and dialysis vintage in 
group A is a clear indication of a positive selection 
bias towards biopsy for the group foreseen to be of 
higher risk, despite normal renal function. On the 
other hand, the group B patients had slightly worse 
renal function at discharge.
At the end, PBx performed too soon might not 
be useful in detecting SCR in low clinical or immu-
nological risk patients. As nephrologists, we must 
balance that with fact that detecting SCR too late 
might signify we will not be able to reverse its 
pathological processes, and cannot change out-
comes. Hence, we must personalize PBx timing 
according to the patient’s clinical and immuno-
logical risk.
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 CONCLUSION
Protocol kidney transplant biopsies are a well-tol-
erated procedure, that allow for the diagnosis and 
treatment of SCR. In this low immunological risk popu-
lation submitted to very early PBx, 12.5% of patients 
had evidence of SCR, but we found no changes in the 
maintenance immunosuppression. Despite having ini-
tial markers of a higher risk of worse evolution, the 
group of patients submitted to early PBx had a similar 
outcome to the group selected as having a minimal 
risk transplant, who were not biopsied. Many questions 
about protocol biopsies remain unanswered, and until 
then we suggest not performing very early protocol 
biopsy in minimal risk patients. Trials addressing when 
and which patients should be submitted to PBx are 
needed to adequately answer these questions.
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